Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758380 | 0.92 | NR1H4 (0.45) | NR1H4MAPTKMT2AHPGDHIF1A | |
| SCHEMBL3755609 | 0.92 | NR1H4 (0.45) | NR1H4MAPTKMT2AHPGDHIF1A | |
| SCHEMBL3751696 | 0.90 | NR1H4 (0.43) | NR1H4MAPTKMT2AHPGDHIF1A | |
| SCHEMBL3759713 | 0.89 | HIF1A (0.49) | KMT2AHIF1AKDM4ENR4A2MEN1 | |
| SCHEMBL3752980 | 0.88 | NR1H4 (0.45) | NR1H4MAPTKMT2AHPGDHIF1A | |
| SCHEMBL8618332 | 0.84 | HIF1A (0.50) | HIF1AKDM4ENR4A2PTPN1PTPRC | |
| SCHEMBL8618330 | 0.84 | HIF1A (0.50) | HIF1AKDM4ENR4A2PTPN1PTPRC | |
| SCHEMBL3751654 | 0.82 | HIF1A (0.52) | KMT2AHIF1AKDM4ENR4A2MAOA | |
| SCHEMBL3755404 | 0.80 | HIF1A (0.61) | NR1H4MAPTKMT2AHPGDHIF1A | |
| SCHEMBL8618307 | 0.80 | HIF1A (0.48) | HIF1AKDM4ENR4A2PTPN1PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231591-B1 | METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME | KYUNG NONG CORP (KR) | 2015-02-11 | — | — | EP | claimed |
| US-8410302-B2 | Methoxyimino compounds and fungicide composition comprising same | KYUNG NONG CORPORATION (KR) | 2013-04-02 | — | — | US | claimed |
| US-20100298593-A1 | METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME | KYUNG NONG CORPORATION (KR) | 2010-11-25 | — | — | US | claimed |
| EP-2231591-B1 | METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME | KYUNG NONG CORP (KR) | 2015-02-11 | — | — | EP | disclosed |
| US-8410302-B2 | Methoxyimino compounds and fungicide composition comprising same | KYUNG NONG CORPORATION (KR) | 2013-04-02 | — | — | US | disclosed |
| US-20100298593-A1 | METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME | KYUNG NONG CORPORATION (KR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298593-A1 | METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION COMPRISING SAME | CYP51A1, MSMO1, MTMR1 | NR1H4 3791/4885MAPT 1657/4885KMT2A 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.